The role of chemotherapy and new targeted agents in the management of primary prostate cancer

Sanjeev Srinivas Kumar and Simon Pacey

Abstract
While early treatment of primary prostate cancer is very effective, the incidence of primary prostate cancer continues to rise and therefore the detection of men with high-risk non-metastatic prostate cancer and their subsequent management is becoming increasingly important. There continues to be no molecularly-targeted or chemotherapeutic options with proven, statistically significant survival benefit in this setting. However, there are indications that further risk stratification using molecular features could potentially help distinguish indolent from aggressive prostate cancer, ultimately providing biological markers that could guide a more personalised approach to therapy selection.

Keywords
Prostate, primary, cancer, neoadjuvant, adjuvant, hormone therapy, chemotherapy, targeted therapy, molecular, personalised therapy

Date received: 21 July 2016; accepted: 14 November 2016

Introduction
Prostate cancer is the second most common cancer in men.1–3 Nearly 90% of prostate cancers are clinically localised at the time of diagnosis.4,5 The clinical course of localised prostate cancer is highly variable. While many patients have indolent cancers (cured with initial therapy, or observed and treated on progression), other patients have aggressive cancer that will recur after initial treatment. It is estimated that around 15% of all prostate cancer diagnoses could be classified as ‘high-risk’ disease.6 The 10-year survival rate for men with high-risk prostate cancer has been reported to range from 65% to 91%, and an increasing aggregate of high-risk features correlates with worse outcome.7 For a full review of the classification and therapy of high-risk prostate cancer, readers are directed to a review by Chang and colleagues.8

Systemic chemotherapy in addition to definitive management to reduce the chance of recurrence and ultimately death from cancer has a proven role in certain tumour types such as breast, colorectal, bladder or lung cancers. Chemotherapy is given before (neoadjuvant) or just after (adjuvant) definitive therapy (surgery and/or radiotherapy). Often the overall benefit to the treated population may appear numerically small, for example; five-year overall survival (OS) rates for patients with bladder cancer increases by around 5% following neoadjuvant chemotherapy.9 Comparatively few advances have been made to
define additional systemic therapy for men with prostate cancer.

Localised prostate cancer is commonly risk stratified into low-, intermediate- or high-risk, most widely by the D’Amico classification using prostate-specific antigen (PSA) and histological criteria. It is plausible that such classifications may not adequately define populations of men with prostate cancer for additional medical therapy, which has hampered clinical trial design. It is possible that clinical signals of activity from subgroups of patients might have been diluted in a heterogeneous, larger population of men with prostate cancer that did not require additional treatment. Advances in risk stratification may better define populations of men to enter into peri-operative studies; for example, the utility of genomic tests such as Prolaris and Oncotype DX are being investigated to support treatment decisions for men with prostate cancer.

Androgen ablation has been the mainstay of medical treatment for men with prostate cancer since the 1940s. However, drug therapy for men with late-stage ‘castration-resistant’ prostate cancer (CRPC) has altered markedly in the last decade. Several drugs (i.e. cabazitaxel, abiraterone, enzalutamide, alphanadin, sipuleucil T), with varying mechanisms of action, have been approved based on improved OS within randomised clinical trials. Also, reflecting a new paradigm of early systemic treatment, advances in risk stratification may better define populations of men to enter into peri-operative studies; for example, the utility of genomic tests such as Prolaris and Oncotype DX are being investigated to support treatment decisions for men with prostate cancer.

Androgen ablation has been the mainstay of medical treatment for men with prostate cancer since the 1940s. However, drug therapy for men with late-stage ‘castration-resistant’ prostate cancer (CRPC) has altered markedly in the last decade. Several drugs (i.e. cabazitaxel, abiraterone, enzalutamide, alphanadin, sipuleucil T), with varying mechanisms of action, have been approved based on improved OS within randomised clinical trials. Also, reflecting a new paradigm of early systemic treatment, recent and compelling evidence has altered clinical practice. Multiple studies have confirmed docetaxel chemotherapy given to men with hormone-sensitive prostate cancer improved overall survival.11–14

Current neoadjuvant and adjuvant hormonal therapy practice

The role of neoadjuvant hormonal therapy prior to prostatectomy has not been well established15,16 and the clinical trial data have been reviewed by McKay and colleagues.17 Furthermore, the morphological changes induced by neoadjuvant androgen ablation may complicate assessment of surgical margins and capsular involvement.18

Adjuvant androgen-deprivation therapy (ADT), after radical prostatectomy (RP), is restricted to cases with positive pelvic lymph nodes. Trials in this setting report mixed findings; for example a study by Messing et al.19 demonstrated improvement in OS for patients treated with immediate ADT (hazard ratio (HR) 1.84; 95% confidence interval (CI) 1.01–3.35). However, a subsequent meta-analysis of 731 men with positive nodes failed to demonstrate a survival benefit of ADT initiated within four months of RP compared to observation.20

For patients that are treated with radiotherapy, neoadjuvant or adjuvant ADT combined with radiation therapy (RT) are part of current standard practice for men with intermediate and high-risk localised prostate cancer.21 Improved OS and cancer-specific survival data from multiple studies22–26 have reinforced the recommendation that men without significant comorbidities should be offered six months of ADT before, during or after radical external beam radiotherapy. Consideration of continuing ADT for up to three years should be made in men with high-risk disease alone, supported by data suggesting improvements in OS of up to 13% compared to short-term suppression.27–29

Adjuvant and neoadjuvant chemotherapy

The role of neoadjuvant chemotherapy has not been established in the treatment of prostate cancer when given with or without androgen deprivation.17 Previous, small, phase 2 studies have investigated single-agent docetaxel or combination therapy, e.g. docetaxel and estramustine or estramustine and etoposide.30–32 In general, authors conclude neoadjuvant chemotherapy may have a role in treatment of high-risk or locally advanced prostate cancer. However, evidence of survival benefit from randomised clinical trials has yet to be reported. Maturation of data within the Phase III GETUG 12 and SWOG (NCT00430183) trials is awaited. Early results reported from GETUG 12 support an improvement in relapse-free survival following docetaxel chemotherapy.34,35

Adjuvant chemotherapy to treat men with prostate cancer also remains contentious. For example, the RTOG 9902 trial compared ADT and RT vs. ADT and RT followed by chemotherapy (paclitaxel, estramustine and etoposide) for men with localised, high-risk prostate cancer. This study reported increased toxicity with no OS benefit from the investigational arm.36,37 The RTOG 0521 study compared outcomes in 562 men with high-risk, localised prostate cancer treated with two years of androgen suppression plus RT, with or without the addition of adjuvant chemotherapy (docetaxel and prednisone). Preliminary results reported a trend to improved OS at four years (93% vs. 86%) for men treated with adjuvant docetaxel; a short OS assessment was incorporated and additional follow-up to determine long-term benefits was recommended.38 A further study, SWOG 9921, that compared adjuvant therapy (ADT alone or combined with mitoxantrone) was terminated early due to a safety issue.

Adjuvant and neoadjuvant targeted therapies

To date, early prostate cancer treatment decisions are still based almost exclusively on histological architecture (Gleason score)39,40 PSA levels41 and local disease extent.12 We are yet to realise the potential of personalisation of therapy with targeted treatments in prostate cancer.

Prior to addressing the full scope of potential in (neo) adjuvant targeted therapies, addressing new ways of targeting the androgen receptor should be discussed first. Markers
of biological response and resistance have been reported in small studies of neoadjuvant ADT. In a study by Mostaghel et al., evaluating the effect of neoadjuvant ADT on gene expression in RP samples from men with localized prostate cancer, chemical castration was found to reduce tissue androgens by 75% and reduce the expression of several androgen-regulated genes (e.g. NDRG1, FKBP5 and TPMRESS2). However, androgen receptor (AR) and PSA gene expression were not suppressed, suggesting that suboptimal suppression of the AR axis at the tumoural level may lead to resistance in a low androgen environment. A different study by Mostaghel et al. looked at the correlation between tissue androgen levels (dihydrotestosterone and testosterone) and change in tumour volumes after three months of various combinations of neoadjuvant hormonal therapies, but found none. These studies serve to emphasise the need for novel therapies targeting complete suppression of the AR axis, to aid in improving local and systemic control of intermediate to high-risk prostate cancer.

 Gonadotropin-releasing hormone (GnRH) antagonists such as degarelix offer an alternative to luteinising hormone-releasing hormone (LHRH) agonists, as a result of immediate competitive binding to GnRH receptors. Abiraterone is also being assessed in the neoadjuvant setting in combination with an LHRH agonist, and preliminary results have shown that tissue androgens were significantly more suppressed with abiraterone and pathologic responses were favourable. In another study, androgen signalling and proliferation suppression was again more profound with the combination of abiraterone plus an LHRH agonist, compared to LHRH monotherapy. Similarly, investigations into enzalutamide are ongoing.

Better understanding of prostate cancer biology and the ability to adapt therapy to specific patients and their cancers remains the subject of active research, reviewed by Fraser and colleagues. Recent studies show that prostate cancer can be stratified according to molecular signatures. The genetic changes associated with aggressive prostate cancer, when present in early tumours, herald the onset of early biochemical relapse. The Cancer Genome Atlas (TCGA), a comprehensive molecular analysis of 333 primary prostate carcinomas, has revealed a ‘molecular taxonomy’ in which 74% of analysed tumours fell into one of seven subtypes defined by specific gene fusions (ETS family, SPOP, FOXA1 or IDH1) or molecular defects in signalling pathways such as PI3K, mitogen-activated protein kinase (MAPK) or DNA repair. This effort though still leaves 26% of tumours unclassified. Similarly, the CamCap study group also undertook a comprehensive, integrated analysis of genomic and transcriptomic data from a study of 482 tumour, benign and germline samples, including 259 men with primary prostate cancer. Five distinct molecular profiles for primary prostate cancer were identified that were predictive of biochemical relapse, based on the integrative analysis of transcript levels and somatic copy number alterations (CNAs). Other studies have also used whole-genome sequencing to characterise tumour heterogeneity and improve our understanding of how the subclonal architecture and diversity of tumours changes during metastasis and progression to lethality.

Building from these studies, work is ongoing to develop personalised or precision medicine treatment for men with prostate cancer.

Published studies to date have focussed on targets that may be more relevant in CRPC and usually have been performed in populations without the aid of biomarker selection to enrich the patient population for those most likely to benefit. Examples include studies targeting angiogenesis and vascular endothelial growth factor receptor (VEGFR) (with agents such as bevacizumab, sunitinib and thalidomide), EGFR (gefitinib and cetuximab), platelet-derived growth factor receptor (PDGFR) (imatinib), clusterin (OGX-011 or custirsen) and immunotherapeutics (Sipuleucel-T and Ipilimumab). With all agents, results have been variable, but most promising with targeting of clusterin and immunomodulation; however, they raise important and unresolved issues in regards to appropriate lengths of treatment, and need for predictive biomarkers of response in the setting of prohibitive costs.

A paucity of representative pre-clinical models related to early human prostate cancer makes it attractive to study a drug’s effects in the “window” prior to radical therapy. Ongoing clinical studies from several groups, including ours, may provide further insights (see Table 1). NCT00430183 is a large (>700 patients) study which has completed recruitment and will compare the outcome for patients who have been treated with neoadjuvant docetaxel. The other studies listed are mostly smaller, Phase 1 and 2 studies looking for signals of activity. For example, in addition to the data from the prostate TCGA described above, aberrant PI3k pathway signalling has been detected in 42% of primary and 100% of metastatic prostate cancers. Loss of PTEN and activation of the PI3k/mTOR pathway are observed in aggressive primary disease. The effects in prostate cancer tissue of rapamycin (an mTOR1 inhibitor) have been studied. The drug was safe and inhibited mTORC1 signalling; however, no effects on tumour proliferation were detected. The CaNCaP02 study (Table 1) is investigating the pharmacodynamic effects of AZD2014 (a dual mTORC1 and 2 inhibitor) for men with intermediate- or high-risk prostate cancer. Inhibition of both mTOR complexes may potentially offer improved therapeutic advantages, and results are awaited.

Additional, more immediately actionable opportunities for targeted therapy might exist. An estimated 19% of primary prostate cancers have defects in ‘DNA repair pathways’. Exciting data from the ‘TOPARP’ study confirmed olaparib (PARP inhibitor) treatment was clinically effective when given to men with metastatic CRPC, selected on the basis of defects in DNA repair genes (including
Table 1. Recruiting neoadjuvant studies (from www.clinicaltrials.gov, accessed December 2015).

| ClinicalTrials.gov identifier | Intervention                                                                 | Primary outcome                                                                 |
|-------------------------------|------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| NCT00430183                  | Six cycles docetaxel + LHRH agonist + surgical intervention vs. standard surgical intervention (± adjuvant EBRT in either arm) (>700 patients) | Three-year biochemical progression-free survival rate                             |
| NCT01804712                  | 28 days rituximab (anti CD20 antibody)                                        | Histological 'response rate'                                                     |
| NCT02494713                  | Four months degarelix combined with chemotherapy (doxorubicin, ketoconazole, docetaxel and estramustine) | Pathological response (% tumour burden remaining)                                 |
| NCT02381236                  | 84 days G-202 (pro-drug, coupled to PSMA)                                     | Prostate volume and perfusion of using multiparametric prostate (mp) MRI         |
| NCT02268175                  | Six cycles of Enzalutamide + Leuprolide + Abiraterone Acetate + Prednisone vs. Enzalutamide + Leuprolide | Pathological: pCR and MRD                                                        |
| NCT01409200                  | Eight months ADT ± open-label Axitinib (VEGFR, c-kit, PDGFR inhibitor)         | PFS at 12 months after surgery                                                   |
| NCT02160353                  | 126 days abiraterone acetate + prednisolone + GnRH agonist                    | Clinical tumour, biochemical and prostate volume response                         |
| NCT02643667                  | 28 days Ibrutinib (BTK inhibitor)                                             | Prostate immune infiltration compared to a reference cohort                       |
| NCT01990196                  | Six to eight weeks with three groups: Degarelix + enzalutamide vs. trametinib (MEK) + degarelix + enzalutamide vs. dasatinib (SRC and Bcr-Abl inhibitor) + degarelix + enzalutamide | N cadherin and vimentin expression                                                |
| NCT02153918                  | Three months rV-PSA (L155)-TRICOM (PROSTVAC-V) as a priming vaccination followed by monthly boosting with rF-PSA (L155)-TRICOM (PROSTVAC-F) | CD4 and CD8 cell infiltrates                                                     |
| NCT02064608                  | Two weeks AZD2014 (mTOR 1/2 inhibitor)                                        | mTORC1 and mTORC2 pathway inhibition using IHC for p4EBP1, pS6 and pAKT         |
| NCT01832259                  | 28 days of pazopanib (cKIT, FGFR, PDGFR and VEGFR inhibitor) vs. placebo       | Decrease in pre-metastatic niche formation in benign lymph nodes                 |
| NCT02390063                  | ChAdOx1 ST4 prime followed by two boosts of MVA ST4 vaccine (q4 week) vs. one week of low-dose cyclophosphamide pre-conditioning before each vaccination vs. three MVA ST4 vaccinations alone (q4 week) vs. one week of low-dose cyclophosphamide pre-conditioning before each of the three MVA ST4 vaccinations | Vaccine safety and immunogenicity (by change in anti-ST4 cellular and humoral responses following vaccination) |

NCT: National Clinical Trial; LHRH: lutropinizing hormone-releasing hormone; EBRT: external-beam radiation therapy; PSMA: prostate-specific membrane antigen; ADT: androgen-deprivation therapy; VEGFR: vascular endothelial growth factor receptor; PDGFR: platelet-derived growth factor receptor; GnRH: gonadotropin-releasing hormone; BTK: Bruton tyrosine kinase; rV-PSA: recombinant vaccinia virus expressing prostate-specific antigen; rF-PSA: recombinant fowlpox prostate-specific antigen; mTOR: mammalian target of rapamycin; FGFR: fibroblast growth factor receptor; pCR: pathological complete response; MRD: minimal residual disease; PFS: progression-free survival; IHC: immunohistochemistry.

BRCA1/2, ATM, Fanconi’s anaemia genes, and CHEK2). A further window study, using olaparib (CaNCaPO3), has been developed and is scheduled to open to recruitment later in 2016.

It is worth noting the variety of endpoints that are employed within the studies listed in Tables 1 and 2. One of the challenges for investigators in this field remains defining and obtaining consensus on what are adequate surrogate endpoints for prostate cancer relapse, or alternatively, clinically relevant endpoints such as OS will have to be used (even if the studies take longer to complete). Surrogate endpoints such as pathological complete response (pCR) rate, validated in other solid tumours to correlate with improved survival, have not been proven in prostate cancer. Advances
in technology may improve this situation; for example, it is possible to measure circulating tumour DNA (ctDNA) in a variety of clinical settings including prostate cancer. With further refinement it will be interesting to see if measuring ctDNA, or perhaps another circulating marker, might more adequately monitor the response to drug treatment.

**Conclusion**

As the incidence of primary prostate cancer rises in the United Kingdom, the detection of men with high-risk non-metastatic prostate cancer and their subsequent management is becoming increasingly important. Over the last decade, there has been a significant shift in the management of prostate cancer, including studies that confirm the benefits of radical treatment in a number of publications. Building on results for men with CRPC, docetaxel has recently been proven active for men with hormone-sensitive prostate cancer and the results of studies with more recently approved drugs for prostate cancer in the (neo)adjuvant setting are awaited. Furthermore, advances in the biological understanding of prostate cancer and novel drug development will hopefully broaden the armamentarium beyond agents proven or predicted to be effective in CRPC.

While it is clear that early, radical treatment of primary prostate cancer is very effective, it remains difficult to identify those patients who are likely to relapse and to treat them appropriately. Further risk stratification, for example, utilising molecular features, could potentially help distinguish indolent from aggressive prostate cancer, ultimately providing biological markers that could guide a more personalised approach to therapy selection.

**Key points**

1. An increasing proportion of men diagnosed with prostate cancer in the United Kingdom are presenting with non-metastatic disease.
2. Early treatment of primary prostate cancer is very effective, and radical treatment has been clearly shown to be beneficial in this group of patients in a number of publications.
3. As yet, there continues to be no molecularly targeted or chemotherapeutic options with proven, statistically significant survival benefit in this setting.
4. Identification of men with prostate cancer that is likely to relapse and to treat them appropriately remains an unmet clinical challenge. However, there are indications that further risk stratification using molecular features could potentially help distinguish indolent from aggressive prostate cancer.
5. Using molecular features to personalise treatment could allow us to optimise precision treatment of primary prostate cancer.

Table 2. Recruiting adjuvant studies (from www.clinicaltrials.gov, accessed December 2015).

| ClinicalTrials.gov identifier | Intervention                                                                 | Primary outcome                                         |
|------------------------------|------------------------------------------------------------------------------|---------------------------------------------------------|
| NCT01753297                  | Nine months of triptorelin vs. active surveillance after radical prostatectomy (PRIORITI) | Biochemical relapse-free survival                       |
| NCT02176161                  | Nine months of metformin (patients at high risk of recurrence)               | PSA doubling time over nine months                      |
| NCT02064673                  | Six months curcumin vs. placebo post-prostatectomy                           | Recurrence-free survival (total serum PSA <0.2 ng/ml at three years) |
| NCT01436968                  | Up to six months: ProstAtak™ (immunotherapy) consisting of AdVtk injection + oral valacyclovir (2× pre-radiation, 1× post-standard EBRT), vs. placebo + valaciclovir. Short-term ADT is optional post-upfront RT | Disease-free survival                                   |
| NCT01341652                  | Two years of pTVG-HP (DNA vaccine) with rhGM-CSF vs. rhGM-CSF alone         | Metastasis-free survival                                |
| NCT02446444                  | 24 months of LHRH agonist + enzalutamide vs. LHRH + non-steroidal anti-androgen (and EBRT ± brachytherapy boost approx. 16 weeks after randomisation) for high-risk, clinically localised, prostate cancer: ‘ENZARAD’ | Overall survival                                        |
| NCT02229734                  | Stereotactic radiation + 18 months ADT, high-risk prostate cancer: ‘FASTR-2’ | GI and GU toxicity at one year                           |

NCT: National Clinical Trial; PSA: prostate-specific antigen; EBRT: external-beam radiation therapy; ADT: androgen-deprivation therapy; RT: radiation therapy; rhGM-CSF: recombinant human granulocyte-macrophage-colony-stimulating factor; LHRH: luteinizing hormone-releasing hormone; GI: gastrointestinal; GU: genitourinary.
Conflicting interests
The authors declare that there is no conflict of interest.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Ethical approval
Not applicable.

Informed consent
Not applicable.

Guarantor
SP.

Contributorship
Both SSK and SP researched the literature and analysed the current evidence. SSK prepared the first draft of the manuscript. Both SSK and SP reviewed and edited the manuscript and approved the final version of the manuscript.

Acknowledgements
None.

References
1. Cancer Research UK. www.cancerresearchuk.org
2. Centers for Disease Control. www.cdc.gov
3. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0. Cancer incidence and mortality worldwide: IARC CancerBase, No. 11. Lyon, France: International Agency for Research on Cancer, 2013.
4. Penney KL, Stampfer MJ, Jahn JL, et al. Gleason grade progression is uncommon. Cancer Res 2013; 73: 5163–5168.
5. National Institutes of Health. National Cancer Institute. http://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq
6. Cooperberg MR, Broering JM and Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28: 1117–1123.
7. Spahn M, Joniau S, Gontero P, et al. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20ng/mL: A European multi-institutional study of 712 patients. Eur Urol 2010; 58: 1–7.
8. Chang AJ, Autio KA, Roach M 3rd, et al. High-risk prostate cancer – classification and therapy. Nat Rev Clin Oncol 2014; 11: 308–323.
9. ABC Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systemic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005; 48: 202–205.
10. D’Amico AV, Whittington R, Malkowicz SB, et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999; 17: 168–172.
11. James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016; 387: 1163–1177.
12. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015; 373: 737–746.
13. Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14: 149–158.
14. Gravis G, Boher JM, Joly F, et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non-castrate prostate cancer: Impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol 2016; 70: 256–262.
15. Wijtjes WP, Schulman CC and Debruyne FM. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2–3 N0 M0 prostate carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Urology 1997; 49 (3A Suppl): 65–69.
16. Fair WR, Cookson MS, Stroumbakis N, et al. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology 1997; 49 (3A Suppl): 46–55.
17. McKay RR, Choueiri TK and Taplin ME. Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer. Drugs 2013; 73: 1417–1430.
18. Bazinet M, Zheng W, Bégin LR, et al. Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma. Urology 1997; 49: 721–725.
19. Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 472–479.
20. Wong YN, Freedland S, Egleston B, et al. Role of androgen deprivation therapy for node-positive prostate cancer. J Clin Oncol 2009; 27: 100–105.
21. National Institute for Health and Care Excellence. Prostate cancer: Diagnosis and management, https://www.nice.org.uk/guidance/cg175/chapter/1-recommendations
22. Boilla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010; 11: 1066–1073.
23. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of phase III RTOG 85–31. Int J Radiat Oncol Biol Phys 2005; 61: 1285–1290.
24. Mason MD, Parulekar WR, Sydes MR, et al. Final report of the Intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation...
therapy alone in locally advanced prostate cancer. *J Clin Oncol* 2015; 33: 2143–2150.

25. Warde P, Mason M, Ding K, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: A randomised, phase 3 trial. *Lancet* 2011; 378: 2104–2111.

26. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomised phase III trial. *Lancet* 2009; 373: 301–308.

27. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92–02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. *J Clin Oncol* 2008; 26: 2497–2504.

28. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. *N Engl J Med* 2009; 360: 2516–2527.

29. Souhami L, Bae K, Pilepich M, et al. Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: A secondary analysis of RT0G 85–31. *J Clin Oncol* 2009; 27: 2137–2143.

30. Hussain M, Smith DC, El-Rayes BF, et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. *Urology* 2003; 61: 774–780.

31. Kim WY, Whang YE, Pruthi RS, et al. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: A phase II trial. *Urol Oncol* 2011; 29: 608–613.

32. Febbo PG, Richie JP, George DJ, et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. *Clin Cancer Res* 2005; 11: 5233–5240.

33. Clark PE, Peerboom DM, Dreicer R, et al. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. *Urology* 2001; 57: 281–285.

34. Fizazi K, Lesaunier F, Delva R, et al. A phase III trial of docetaxel/estramustine in high-risk localized prostate cancer: A planned analysis of response, toxicity and quality of life in the GETUG 12 trial. *Eur J Cancer* 2012; 48: 209–217.

35. Fizazi K, Lasaunier F, Delva R, et al. A phase III trial of docetaxel/estramustine in high-risk localized prostate cancer: Preliminary results of a randomized phase II study. *J Urol* 2015; 194: 2516–2527.

36. Rosenthal SA, Bae K, Pienta KJ, et al. Phase III multinstitutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: Preliminary toxicity analysis of RTOG 99–02. *Int J Radiat Oncol Biol Phys* 2009; 73: 672–678.

37. Sandler HM, Hunt D and Sartor AO. A phase III protocol of androgen suppression (AS) and radiation therapy (RT) versus AS and RT followed by chemotherapy with paclitaxel, estramustine, and etoposide (TEE) for localized, high-risk, prostate cancer, RTOG 9902. Presented at: 2010 American Society of Clinical Oncology Annual Meeting, Abstract 4632.

38. Sandler HM, Hu C, Rosenthal SA, et al. A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). Presented at: 2015 American Society of Clinical Oncology Annual Meeting, Abstract 5002.

39. Gleason DF. Classification of prostatic carcinomas. *Cancer Chemother Rep* 1966; 50: 125–128.

40. Gleason DF and Mellinger GT. The Veterans Administration Cooperative Urological Research Group. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. *J Clin Oncol* 1974; 11: 58–64.

41. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men. *J Urol* 1994; 151: 1283–1290.

42. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate cancer. V.1.2015, http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

43. Mostaghel EA, Page ST, Lin DW, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer. *Cancer Res* 2007; 67: 5033–5041.

44. Mostaghel EA, Nelson P, Lange PH, et al. Neoadjuvant androgen pathway suppression prior to prostatectomy. *ASCO Meeting Abstracts* 2012; 30: 4520.

45. Shaw GL, Whitaker H, Corcoran M, et al. The early effects of rapid androgen deprivation on human prostate cancer. *Eur Urol* 2016; 70: 214–218.

46. Taplin ME, Montgomery RB, Logothetis C, et al. Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study. *ASCO Meeting Abstracts* 2012; 30: 4521.

47. Efstratiou E, Davis JW, Troncoso P, et al. Cytoreduction and androgen signaling modulation by abiraterone acetate (AA) plus leuprolide acetate (LHRHa) versus LHRHa in localized high-risk prostate cancer (PCa): Preliminary results of a randomized preoperative study. *ASCO Meeting Abstracts* 2012; 30: 4556.

48. Fraser M, Berlin A, Bristow RG, et al. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. *Urol Oncol* 2015; 33: 85–94.

49. Glinksky GV, Glinskii AB, Stephenson AJ, et al. Gene expression profiling predicts clinical outcome of prostate cancer. *J Clin Invest* 2004; 113: 913–923.

50. Varambally S, Yu J, Laxman B, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. *Cancer Cell* 2005; 8: 393–406.

51. Irshad S, Bansal M, Castillo-Martin M, et al. A molecular signature predictive of indolent prostate cancer. *Sci Transl Med* 2013; 5: 202ra122.
53. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11–22.
54. Ramos-Montoya A, Lamb AD, Russell R, et al. HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network. EMBO Mol Med 2014; 6: 651–661.
55. The Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 2015; 163: 1011–1025.
56. Ross-Adams H, Lamb AD, Dunning MJ, et al. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study. EBioMedicine 2015; 2: 1133–1144.
57. Cooper CS, Eeles R, Wedge DC, et al. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet 2015; 47: 367–372.
58. Gundem G, Van Loo P, Kremeyer B, et al. The evolutionary history of lethal metastatic prostate cancer. Nature 2015; 520: 353–357.
59. Hong MK, Macintyre G, Wedge DC, et al. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat Commun 2015; 6: 6605.
60. Ross RW, Galsky MD, Febbo P, et al. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: A Prostate Cancer Clinical Trials Consortium trial. Cancer 2012; 118: 4777–4784.
61. Zurita AJ, Ward JF, Araujo JC, et al. Neoadjuvant trial of sunitinib malate and androgen ablation (ADT) in patients with localized prostate cancer (PCa) at high risk for recurrence. ASCO Meeting Abstracts 2011; 29: 143.
62. Efstathiou E, Troncoso P, Wen L, et al. Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors. Sci Signal 2015; 8: ra116.
63. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11–22.
64. Malik SN, Brattain M, Ghosh PM, et al. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002; 8: 1168–1171.
65. Morgan TM, Koreckij TD and Corey E. Targeted therapy for advanced prostate cancer: Inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets 2009; 9: 237–249.
66. Armstrong AJ, Netto GJ, Rudek MA, et al. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin Cancer Res 2010; 16: 3057–3066.
67. Matejo C, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 2015; 373: 1697–1708.
68. Greenberg DC, Lophatathanon A, Wright KA, et al. Trends and outcome from radical therapy for primary non-metastatic prostate cancer in a UK population. PLoS One 2015; 10: e0119494.
69. Gnanapragasam VJ, Payne H, Syndikus I, et al. Primary radical therapy selection in high-risk non-metastatic prostate cancer. Clin Oncol (R Coll Radiol) 2015; 27: 136–144.